Repare Therapeutics Provides Business Update and Reports Fir

Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting


Camonsertib combination therapy... | May 9, 2023

Related Keywords

Canada , United States , Ukraine , Russia , Canadian , American , Lloydm Segal , Daniel Belanger , Susan Molineaux , Jerel Davis , Canadian Cancer Trials Group , Exchange Commission , Repare Therapeutics Inc , Linkedin , American Association For Cancer Research , Company Nasdaq , Company Annual Report On Form , Repare Therapeutics , Chief Executive Officer , Operational Updates , Clinical Trials Plenary Session , Cancer Research , Managing Director , Versant Ventures , Private Securities Litigation Reform Act , Annual Report , Des March , Repare Therapeutics Inc Stock Exchange , News , Nformation , Ress Release , Eported , Nitial , Amonsertib , Ata , Rom , Ngoing , Hase , Presr , Nd , Ttacc , Linical , Rials , N , Plenary , Ral , Resentation , T , 023 , Acr , Nnual , Ombination Rptx Us7602731025 ,